Gene Therapy Market Competitive Landscape Report 2026: Comprehensive Insights About 180+ Companies and 200+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Taysha Gene Therapies (TSHA) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress [Yahoo! Finance]
Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA) [Yahoo! Finance]